Mizuho reaffirmed their buy rating on shares of Akebia Therapeutics (NASDAQ:AKBA) in a report issued on Tuesday morning, AnalystRatings.com reports. The brokerage currently has a $17.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Akebia Therapeutics from a buy rating to a hold rating in a research report on Wednesday, July 15th. Morgan Stanley boosted their price objective on shares of Akebia Therapeutics from $11.00 to $12.00 and gave the stock an equal weight rating in a research note on Wednesday, July 15th. ValuEngine lowered shares of Akebia Therapeutics from a buy rating to a hold rating in a research note on Monday, July 13th. Royal Bank of Canada boosted their price objective on shares of Akebia Therapeutics from $8.00 to $12.00 and gave the stock a sector perform rating in a research note on Wednesday, May 6th. Finally, BidaskClub lowered shares of Akebia Therapeutics from a buy rating to a hold rating in a research note on Saturday, July 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. Akebia Therapeutics currently has an average rating of Hold and a consensus target price of $15.57.

Shares of AKBA opened at $10.50 on Tuesday. The company has a 50 day moving average price of $11.99 and a 200-day moving average price of $9.84. Akebia Therapeutics has a fifty-two week low of $2.99 and a fifty-two week high of $13.71. The stock has a market capitalization of $1.39 billion, a PE ratio of -3.50 and a beta of 1.41. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.07 and a current ratio of 1.59.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.02. Akebia Therapeutics had a negative net margin of 113.35% and a negative return on equity of 54.01%. Equities research analysts forecast that Akebia Therapeutics will post -1.59 EPS for the current year.

In other Akebia Therapeutics news, insider Dell Faulkingham sold 6,426 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $11.58, for a total transaction of $74,413.08. Following the transaction, the insider now owns 73,574 shares in the company, valued at approximately $851,986.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Maxine Gowen sold 4,567 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $11.84, for a total transaction of $54,073.28. Corporate insiders own 2.55% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Sofinnova Investments Inc. acquired a new stake in shares of Akebia Therapeutics in the second quarter worth $9,261,000. FMR LLC increased its stake in shares of Akebia Therapeutics by 72.7% in the second quarter. FMR LLC now owns 1,771,567 shares of the biopharmaceutical company’s stock worth $24,058,000 after acquiring an additional 745,500 shares during the period. Federated Hermes Inc. acquired a new stake in shares of Akebia Therapeutics in the second quarter worth $3,707,000. Marshall Wace North America L.P. acquired a new stake in shares of Akebia Therapeutics in the second quarter worth $5,864,000. Finally, Marshall Wace LLP acquired a new stake in shares of Akebia Therapeutics in the second quarter worth $4,902,000. Institutional investors and hedge funds own 70.08% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.

Featured Story: New Google Finance Tool and Screening Stocks

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.